Aurinia Pharmaceuticals (AUPH) Cash from Financing Activities (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Cash from Financing Activities data on file, last reported at -$53.7 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 8.81% year-over-year to -$53.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$110.5 million (down 32.48% YoY) and the FY2025 annual result came in at -$106.1 million, down 116.15% from the prior year.
• Cash from Financing Activities declined to -$53.7 million in Q1 2026, from -$1.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.6 million in Q1 2023 to a low of -$53.7 million in Q1 2026.
• A 5-year average of -$13.2 million and a median of -$4.1 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 304.69% — and 2024, when it sank 1018.3%.
• Tracing AUPH's Cash from Financing Activities over 5 years: stood at $688000.0 in 2022, then plunged by 910.61% to -$5.6 million in 2023, then tumbled by 313.23% to -$23.0 million in 2024, then surged by 91.8% to -$1.9 million in 2025, then tumbled by 2741.98% to -$53.7 million in 2026.
• The last three Cash from Financing Activities figures came in at -$53.7 million (Q1 2026), -$1.9 million (Q4 2025), and -$10.5 million (Q3 2025), per Business Quant data.